Overview

A Trial Evaluating TG4050 in Ovarian Carcinoma.

Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.
Phase:
Phase 1
Details
Lead Sponsor:
Transgene